No Data
Jiangxi Wannianqing Cement to Undertake Convertible Bond Buyback
Jiangxi Wannianqing Cement (000789.SZ): First repurchase of 0.2941 million shares involving 1.4907 million yuan.
On February 11, Glonghui reported that Jiangxi Wannianqing Cement (000789.SZ) announced that on February 11, 2025, it would first repurchase 0.2941 million shares of the company through a dedicated repurchase securities account using centralized bidding, accounting for 0.04% of the company's total share capital; the lowest fill price for the initial repurchase was 5.04 yuan/share, the highest fill price was 5.09 yuan/share, and the total amount of the transaction was 1.490705 million yuan (excluding stamp tax, transaction commission, and other transaction fees).
Yue Jiangxi Wannianqing Cement (301111.SZ) plans to increase investment in its controlling subsidiary Jiangxi Wannianqing Cement Pharmaceutical by 22.8 million yuan.
Yue Jiangxi Wannianqing Cement (301111.SZ) issued an announcement that its controlling subsidiary, Guangdong Jiangxi Wannianqing Pharmaceutical Co., Ltd. (the following...)
Wan Nianqing: 2024 Annual Results Forecast
Jiangxi Wannianqing Cement (000789.SZ): Expected net income for the fiscal year 2024 to decrease by 92.13%-94.75%.
On January 22, Gelonghui announced that Jiangxi Wannianqing Cement (000789.SZ) released its 2024 annual performance forecast, estimating that the Net income attributable to shareholders of the listed company will be between 12 million yuan and -18 million yuan, a decrease of 94.75% to 92.13% compared to the same period last year; after deducting non-recurring gains and losses, the net income is expected to be a loss of 38 million yuan to -19 million yuan, a decline of 120.90% to 110.45% year-on-year; the EPS is expected to be between 0.0150 yuan/share and 0.0226 yuan/share. In 2024, the Cement Industry will be affected by the growth rates of Real Estate Investment and Infrastructure Investment.
Yue Jiangxi Wannianqing Cement (301111.SZ): Currently, there is no production or sales of Pharmaceuticals for the treatment of monkeypox.
On January 13, Gelonghui reported that Jiangxi Wannianqing Cement (301111.SZ) stated on the investor interaction platform that the company currently does not produce or sell any Pharmaceuticals for the treatment of monkeypox.
